SAN ANTONIO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- U.S. Global Investors, Inc. (NASDAQ: GROW) (the “Company”), a registered investment advisory firm1 with deep expertise in global markets and specialized sectors from gold mining to airlines, today announced a net loss of $334,000, or $0.03 per share, for the fiscal year ended June 30, 2025, compared to net income of $1.3 million, or $0.09 per share, during the same period a year earlier. Total operating revenues were $8.5 million, a 23% decrease from the 12 mo ...

TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is happy to announce that it has completed import operations and release to the United States. PharmAla announced contracting of this new distribution site on March 24, 2025. “With the full onboarding of our distribution facility, PharmAla is ...

Continued Sales Momentum Drove 24% YoY Revenue Growth; Acquisition of Crown 1 Enterprises to Further Expand Customer Base, Operating Scale, and Revenue with $56 Million in Sales in 12 Months Ended June 30, 2025 EAST RUTHERFORD, NJ, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Mama’s Creations, Inc. (Nasdaq: MAMA), a leading national marketer and manufacturer of fresh deli prepared foods, today reported its financial results for the second quarter ended July 31, 2025. Financial Summary:   Three Months Ended July 31, $ ...

Wilmington, DE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will now present at the Baird 2025 Global Healthcare Conference at 2:35 p.m. ET on Wednesday, September 10th, 2025. A link to the live audio webcast, as well as a replay, will be available on the Company’s website under the Investors tab at Events and Presentations. ABOUT ENOVIS Enovis Corporation (NYSE: ENOV) is an innovation-driven medical te ...

Ticker symbol to remain “CMPO”SOMERSET, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CompoSecure, Inc. (Nasdaq: CMPO) (“CompoSecure” or the “Company”) today announced that it will transfer the listing of its Class A common stock (Nasdaq: CMPO) to the New York Stock Exchange (“NYSE”) from the Nasdaq Global Market (“Nasdaq”). The Class A common stock will retain their existing stock ticker, CMPO. CompoSecure expects the Class A common stock to begin trading on the NYSE on September 23, 2025, when CompoSecure is e ...

VANCOUVER, British Columbia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Scott Lendrum, CEO of Giga Metals Corp. (TSX.V: GIGA, OTCQB: GIGGF) announced today that following the closing of the non-brokered private placement on August 28, 2025, Giga Metals Corp. will undertake a geophysics program at its flagship Turnagain project in northern British Columbia. Giga has retained Simcoe Geoscience Limited to complete the work, and the initial phase of the program is expected to begin the week of September 15th. The progr ...

OMAHA, Neb., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”) today announced that it has acquired 285,420,000 Dogecoin (“Dogecoin” or “DOGE”), representing approximately US$68 million, through its newly launched and Dogecoin Foundation-backed treasury strategy (the “Official Dogecoin Treasury” or “Treasury”). The Treasury has been established to strategically accumulate DOGE in anticipation of increased utility and adoption, driven by the eff ...

LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it has received a strategic investment from Goose Capital and former Tanox, Inc. CEO Dr. Nancy T. Chang, Goose founding member. At Tanox, Dr. Chang and her team invented and developed FDA-approved XOLAIR® (omalizumab) for severe asthma, TROGARZO® (ibalizu ...

Core Viewpoint - Rapport Therapeutics, Inc. has initiated an underwritten public offering of $250 million in common stock, with an additional option for underwriters to purchase up to $37.5 million more [1][2]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [5]. - The company utilizes a RAP technology platform based on pioneering discoveries related to receptor associated proteins (RAPs) in the brain, aiming to create precision small molecule candidates that address limitations in conventional neurology drug discovery [5]. - The lead investigational drug, RAP-219, targets specific regions of the brain and is being pursued for conditions such as drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain [5]. Offering Details - The public offering is subject to market conditions, and there is no guarantee regarding its completion or the final terms [1]. - The offering is conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3].

At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglycemia, improved levels of euglycemia and improved fasting tolerance Phase 3 results are further supported by early data from open-label Japanese cohort (n=3) where all participants were able to eliminate daily cornstarch while maintaining or improving glycemic control DTX401 was well tolerated with an acceptable safety profile NOVATO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Today, ...